152 related articles for article (PubMed ID: 29458616)
1. Improved Cytotoxic Effect of Doxorubicin by Its Combination with Sclareol in Solid Lipid Nanoparticle Suspension.
Oliveira MS; Lima BHS; Goulart GAC; Mussi SV; Borges GSM; Oréfice RL; Ferreira LAM
J Nanosci Nanotechnol; 2018 Aug; 18(8):5609-5616. PubMed ID: 29458616
[TBL] [Abstract][Full Text] [Related]
2. Sclareol is a potent enhancer of doxorubicin: Evaluation of the free combination and co-loaded nanostructured lipid carriers against breast cancer.
Borges GSM; Silva JO; Fernandes RS; de Souza ÂM; Cassali GD; Yoshida MI; Leite EA; de Barros ALB; Ferreira LAM
Life Sci; 2019 Sep; 232():116678. PubMed ID: 31344429
[TBL] [Abstract][Full Text] [Related]
3. α-Tocopherol succinate improves encapsulation and anticancer activity of doxorubicin loaded in solid lipid nanoparticles.
Oliveira MS; Mussi SV; Gomes DA; Yoshida MI; Frezard F; Carregal VM; Ferreira LAM
Colloids Surf B Biointerfaces; 2016 Apr; 140():246-253. PubMed ID: 26764108
[TBL] [Abstract][Full Text] [Related]
4. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells.
Wong HL; Rauth AM; Bendayan R; Manias JL; Ramaswamy M; Liu Z; Erhan SZ; Wu XY
Pharm Res; 2006 Jul; 23(7):1574-85. PubMed ID: 16786442
[TBL] [Abstract][Full Text] [Related]
5. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
[TBL] [Abstract][Full Text] [Related]
6. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery.
Tam YT; To KK; Chow AH
Colloids Surf B Biointerfaces; 2016 Mar; 139():249-58. PubMed ID: 26724466
[TBL] [Abstract][Full Text] [Related]
7. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
Garg A; Singh S
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of polymyxin-loaded solid lipid nanoparticles (PLX-SLN): Characterization of physicochemical properties and in vitro efficacy.
Severino P; Silveira EF; Loureiro K; Chaud MV; Antonini D; Lancellotti M; Sarmento VH; da Silva CF; Santana MHA; Souto EB
Eur J Pharm Sci; 2017 Aug; 106():177-184. PubMed ID: 28576561
[TBL] [Abstract][Full Text] [Related]
9. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles.
Mussi SV; Silva RC; Oliveira MC; Lucci CM; Azevedo RB; Ferreira LA
Eur J Pharm Sci; 2013 Jan; 48(1-2):282-90. PubMed ID: 23178339
[TBL] [Abstract][Full Text] [Related]
10. Solid lipid nanoparticles co-loaded with doxorubicin and α-tocopherol succinate are effective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell models.
Oliveira MS; Aryasomayajula B; Pattni B; Mussi SV; Ferreira LAM; Torchilin VP
Int J Pharm; 2016 Oct; 512(1):292-300. PubMed ID: 27568499
[TBL] [Abstract][Full Text] [Related]
11. pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells.
Shalviri A; Raval G; Prasad P; Chan C; Liu Q; Heerklotz H; Rauth AM; Wu XY
Eur J Pharm Biopharm; 2012 Nov; 82(3):587-97. PubMed ID: 22995704
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of modified lipid nanoparticles for doxorubicin controlled release.
Ying XY; Du YZ; Chen WW; Yuan H; Hu FQ
Pharmazie; 2008 Dec; 63(12):878-82. PubMed ID: 19177903
[TBL] [Abstract][Full Text] [Related]
13. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
Attama AA; Schicke BC; Paepenmüller T; Müller-Goymann CC
Eur J Pharm Biopharm; 2007 Aug; 67(1):48-57. PubMed ID: 17276663
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-loaded biodegradable self-assembly zein nanoparticle and its anti-cancer effect: Preparation, in vitro evaluation, and cellular uptake.
Dong F; Dong X; Zhou L; Xiao H; Ho PY; Wong MS; Wang Y
Colloids Surf B Biointerfaces; 2016 Apr; 140():324-331. PubMed ID: 26764113
[TBL] [Abstract][Full Text] [Related]
15. Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization.
Islan GA; Tornello PC; Abraham GA; Duran N; Castro GR
Colloids Surf B Biointerfaces; 2016 Jul; 143():168-176. PubMed ID: 27003467
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy.
Han Y; Zhang P; Chen Y; Sun J; Kong F
Int J Mol Med; 2014 Jul; 34(1):191-6. PubMed ID: 24804644
[TBL] [Abstract][Full Text] [Related]
17. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery.
Jose S; Anju SS; Cinu TA; Aleykutty NA; Thomas S; Souto EB
Int J Pharm; 2014 Oct; 474(1-2):6-13. PubMed ID: 25102112
[TBL] [Abstract][Full Text] [Related]
18. Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies.
Battaglia L; Gallarate M; Peira E; Chirio D; Muntoni E; Biasibetti E; Capucchio MT; Valazza A; Panciani PP; Lanotte M; Schiffer D; Annovazzi L; Caldera V; Mellai M; Riganti C
J Pharm Sci; 2014 Jul; 103(7):2157-2165. PubMed ID: 24824141
[TBL] [Abstract][Full Text] [Related]
19. Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin.
Abul Kalam M; Sultana Y; Ali A; Aqil M; Mishra AK; Aljuffali IA; Alshamsan A
J Biomed Mater Res A; 2013 Jun; 101(6):1813-27. PubMed ID: 23255511
[TBL] [Abstract][Full Text] [Related]
20. Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability.
Benival DM; Devarajan PV
Int J Pharm; 2012 Feb; 423(2):554-61. PubMed ID: 22155412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
